Tigris Pharmaceuticals is actively seeking to in-license, acquire or co-develop drugs for cancer.

Tigris' mission is to be on the side of patients, finding solutions to save or improve their lives. Our business model is based on guiding molecules from all stages of development through to successful worldwide approval and launch. We offer large pharmaceutical company expertise but with the agility and speed of a smaller organization. Each product gets our specialized and undivided attention. We build each product development strategy for optimal speed-to-market and with maximum return on the drug development investment.

Tigris has expertise in developing breakthrough products/technologies in all stages of development, including pre-clinical, early- and late-stage clinical development. Our team offers decades of experience in clinical drug development and regulatory affairs, and a track record of gaining FDA and worldwide approvals for multiple oncology products. Our leadership team alone has achieved approval of 15 product indications worldwide and led the initiation of hundreds of clinical trials.

Tigris has also established a growing international presence, offering partners access to additional patient populations and clinical settings. Our office in Mexico City, Mexico (headed by Gerado Alvarez, M.D., General Manager) fields inquiries and will conduct clinical trials for the Spanish-speaking population.

If you are interested in working with Tigris Pharmaceuticals, please contact us directly at: partnering@tigrispharma.com.